Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity

British Journal of Cancer

Volumn 79, Issue 3-4, 1999, Pages 627-630

  Milano, G ^d   Etienne, M C ^d   Pierrefite, V ^a   Barberi Heyob, M ^b   Deporte Fety, R ^c   Renee N ^d  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b CENTRE ALEXIS VAUTRIN   (France)

^c CENTRE RENÉ GAUDUCHEAU   (France)

^d NONE

Author keywords

5 Fluorouracil; Anti cancer drug related toxicity; Dihydropyrimidine dehydrogenase

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; DRUG FATALITY; DRUG TOXICITY; ENZYME ASSAY; ENZYME DEFICIENCY; FEMALE; FRANCE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DIGESTIVE SYSTEM; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; MUCOUS MEMBRANE; NEOPLASMS; NEUTROPENIA; OXIDOREDUCTASES; SEX FACTORS; THROMBOCYTOPENIA;

EID: 0000163968     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690098     Document Type: Article

References (20)

1. Diasio RB and Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16: 215-237
2. Diasio RB, Beavers TL and Carpenter JT (1988) Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil induced toxicity. J Clin Invest 81: 47-51
3. Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renée N, Schneider M, Demard F and Milano G (1994) Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12: 2248-2253
4. Fleming R, Milano G, Thyss A, Etienne MC, Renée N, Schneider M and Demard F (1992) Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52: 2899-2902
5. Fleming RA, Milano G, Gaspard MH, Bargnoux PJ, Thyss A, Plagne R, Renée N, Schneider M and Demard F (1993) Dihydropyrimidine dehydrogenase activity in cancer patients. Eur J Cancer 29: 740-744
6. Floyd RA, Hornbeck GL and Byfield JE et al (1982) Clearance of continuously infused 5-fluorouracil in adults having lung or gastrointestinal carcinoma with or without hepatic metastases. Drug Intell Clin Pharm 16: 665-670
7. Harris BE, Song R, Soong SJ and Diasio RB (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50: 197-201
8. Harris BE, Carpenter JT and Diasio RB (1991) Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmocogenetic syndrome. Cancer 50: 197-201
9. Houyau P, Gay C, Chatelut E, Canal P, Roche H and Milano G (1993) Severe flourouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency. J Natl Cancer Inst 85: 1602-1603
10. Johnston MR, Weang K, Tillmans S, Albin N and Diasio RB (1997) Structural organization of the human dihydropyrimidine dehydrogenase gene. Cancer Res 57: 1660-1663
11. Langer CJ, Hageboutros A, Kloth DD, Roby D and Shaer AH (1996) Acute encephalopathy attributed to 5-FU. Pharmacotherapy 16: 311-313
12. Lu Z, Zhang R and Diasio RB (1993) Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53: 5433-5438
13. Milano G and Etienne MC (1994) Potential importance of dihydropyrimidine dehydrogenase in cancer chemotherapy. Pharmacogenetics 4: 301-306
14. Milano G, Etienne MC, Thyss A, Santini J, Frenay M, Renée N, Schneider M and Demard F (1992) Influence of sex and age on fluorouracil clearance. J Clin Oncol 10: 1171-1175
15. Stenram U (1993) 5-FU toxicity and nutritional deficiencies. Br J Cancer 67: 1157
16. Takimoto CH, Lu ZH, Zhang R, Liang MD, Larson LV, Cantilena LR, Grem JL, Allegra CJ, Diasio RB and Chu E (1996) Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 2: 477-481
17. Thyss A, Milano G, Schneider M and Demard F (1988) Circulating drug levels in patients presenting cardiotoxicity to 5-FU. Eur J Cancer Clin Oncol 24: 1675-1676
18. Tuchman M, Stockeler JS, Kiang DT, O'Dea R, Ramnaraine ML and Mirkia BL (1985) Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med 313: 245-249
19. Wei X, McLeod HL, McMurrough J, Gonzalez FJ and Fernandez-Salguero P (1996) Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 98: 610-615
20. Yokota H, Fernandez-Salguero P, Furuya H, Lin K, McBride OW, Podschum B, Schnackerz KD and Gonzalez FJ (1994) cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria. J Biol Chem 269: 23192-23196